MX9707910A - Vector viral recombinante inducible por la glucosa. - Google Patents

Vector viral recombinante inducible por la glucosa.

Info

Publication number
MX9707910A
MX9707910A MX9707910A MX9707910A MX9707910A MX 9707910 A MX9707910 A MX 9707910A MX 9707910 A MX9707910 A MX 9707910A MX 9707910 A MX9707910 A MX 9707910A MX 9707910 A MX9707910 A MX 9707910A
Authority
MX
Mexico
Prior art keywords
glucose
viral vector
recombinant viral
inducible recombinant
inducible
Prior art date
Application number
MX9707910A
Other languages
English (en)
Inventor
Ruihuan Chen
Bruno Doiron
Axel Kahn
Original Assignee
Inst Nat Sante Rech Med
Rech Medicale
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inst Nat Sante Rech Med, Rech Medicale filed Critical Inst Nat Sante Rech Med
Publication of MX9707910A publication Critical patent/MX9707910A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/62—Insulins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
    • C12N2740/13041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/13043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/008—Vector systems having a special element relevant for transcription cell type or tissue specific enhancer/promoter combination
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/15—Vector systems having a special element relevant for transcription chimeric enhancer/promoter combination
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/80—Vector systems having a special element relevant for transcription from vertebrates
    • C12N2830/85—Vector systems having a special element relevant for transcription from vertebrates mammalian

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Virology (AREA)
  • Veterinary Medicine (AREA)
  • Endocrinology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

La presente invencion se refiere a un virus recombinante defectuoso que comprende al menos un gen heterologo bajo el control de una señal de expresion inducible por la glucosa. La misma también se refiere a cualquier composicion que lo contiene y a las células transformadas con dicho vector.
MX9707910A 1995-04-14 1996-04-12 Vector viral recombinante inducible por la glucosa. MX9707910A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9504558A FR2732978B1 (fr) 1995-04-14 1995-04-14 Vecteur viral recombinant, composition pharmaceutique le contenant et cellules transformees correspondantes
PCT/FR1996/000560 WO1996032489A1 (fr) 1995-04-14 1996-04-12 Vecteur viral recombinant inductible par le glucose

Publications (1)

Publication Number Publication Date
MX9707910A true MX9707910A (es) 1997-11-29

Family

ID=9478162

Family Applications (1)

Application Number Title Priority Date Filing Date
MX9707910A MX9707910A (es) 1995-04-14 1996-04-12 Vector viral recombinante inducible por la glucosa.

Country Status (14)

Country Link
US (1) US6309878B1 (es)
EP (1) EP0821741A1 (es)
JP (1) JPH11503608A (es)
KR (1) KR19980703843A (es)
AU (1) AU715377B2 (es)
BR (1) BR9604938A (es)
CA (1) CA2215987A1 (es)
CZ (1) CZ292564B6 (es)
FR (1) FR2732978B1 (es)
HU (1) HUP9802587A3 (es)
MX (1) MX9707910A (es)
NO (1) NO974726L (es)
SK (1) SK137797A3 (es)
WO (1) WO1996032489A1 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU5257198A (en) * 1996-11-15 1998-06-03 Millennium Pharmaceuticals, Inc. Compositions and methods for treating type ii diabetes involving hnf-4
US6537806B1 (en) * 1998-06-02 2003-03-25 University Of Washington Compositions and methods for treating diabetes
EP1889914A1 (en) * 1999-02-19 2008-02-20 Engene, Inc. Compositions for gene therapy of diabetes
JP2002540175A (ja) 1999-02-19 2002-11-26 ドウアリング，マシユー・ジエイ 糖尿病及び肥満症の経口遺伝子治療
JP3406244B2 (ja) * 1999-04-30 2003-05-12 伊藤ハム株式会社 新規な融合蛋白質からの組み換えインスリンの製造方法
WO2000074056A1 (fr) 1999-05-27 2000-12-07 International Business Machines Corporation Lecteur de disque
WO2002089855A1 (en) * 2001-04-27 2002-11-14 Auckland Uniservices Limited Peroral transduction of hepatocytes in the treatment of disease
DE102005024884A1 (de) * 2005-05-31 2006-12-07 Linde Ag Arbeitsmaschine, insbesondere Flurförderzeug
KR20080036015A (ko) * 2005-06-01 2008-04-24 주식회사 바이오텍 아이 글루코오스 유도성 인슐린 발현 및 당뇨병 치료 방법
ES2325711B1 (es) * 2007-04-17 2010-06-17 Centro De Investigaciones Energeticas, Medioambientales Y Tecnologicas (Ciemat) Vectores de expresion que comprenden el promotor del gen pklr humano y su uso para la elaboracion de composiciones farmaceuticas destinadas a terapia genica somatica con expresion especifica en celulas eritroides.

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992021750A1 (en) * 1991-05-29 1992-12-10 THE UNITED STATES OF AMERICA, represented by THE SCRETARY, DEPARTMENT OF HEALTH & HUMAN SERVICES Eukaryotic expression vectors with regulation of rna processing
DE69233013T2 (de) * 1991-08-20 2004-03-04 The Government Of The United States Of America As Represented By The Secretary Of National Institute Of Health, Office Of Technology Transfer Adenovirus vermittelter gentransfer in den gastrointestinaltrakt
GB9305759D0 (en) * 1993-03-19 1993-05-05 Medical Research Council And T Hiv therapy method and agents
CA2166078A1 (en) * 1993-06-28 1995-01-05 Christopher B. Newgard Vectors for genetically engineered cells that produce insulin in response to glucose

Also Published As

Publication number Publication date
KR19980703843A (ko) 1998-12-05
FR2732978B1 (fr) 1997-05-30
NO974726D0 (no) 1997-10-13
AU5652396A (en) 1996-10-30
BR9604938A (pt) 1998-06-09
HUP9802587A3 (en) 1999-12-28
EP0821741A1 (fr) 1998-02-04
AU715377B2 (en) 2000-02-03
WO1996032489A1 (fr) 1996-10-17
HUP9802587A2 (hu) 1999-02-01
JPH11503608A (ja) 1999-03-30
CA2215987A1 (fr) 1996-10-17
CZ325197A3 (cs) 1998-01-14
CZ292564B6 (cs) 2003-10-15
US6309878B1 (en) 2001-10-30
NO974726L (no) 1997-10-13
FR2732978A1 (fr) 1996-10-18
SK137797A3 (en) 1998-05-06

Similar Documents

Publication Publication Date Title
MX9603002A (es) Procedimiento para la preparacion de virus asociados a los adenovirus (aav), recombinantes, y usos de los mismos.
AU7264694A (en) Defective adenovirus vectors and use thereof in gene therapy
MX9709549A (es) Adenovirus recombinantes, su uso para preparar aav, linea celular complementaria y composiciones farmaceuticas que los contienen.
AU7335296A (en) Recombinant sendai virus
AU681705B2 (en) Endosomolytically active particles
ES8603955A1 (es) Preparacion de igf y egf de humano por tecnologia de adn recombinante
EP0814154A3 (en) Recombinant alphavirus vectors
EP0732340A3 (en) Expression of porcine reproductive respiratory syndrome virus polypeptides in the same cell
AU4653989A (en) Biologically competent, virus inactivated albumin
ZA942778B (en) Recombinant viruses, and their preparation and use in gene therapy.
PT757717E (pt) Vacinas de papilomavirus
AU5729196A (en) Soluble, active hepatitis c virus protease
AU3636189A (en) Hiv-2 virus variants
CA2153068A1 (en) Enhancer sequence for modulating expression in epithelial cells
MX9707910A (es) Vector viral recombinante inducible por la glucosa.
AU7234987A (en) Viral vector coding for a glycoprotein of the virus responsible for a.i.d.s., vaccine and antibody
AU5320296A (en) Modified viral envelope polypeptide
AU7691191A (en) Recombinant spider silk proteins through genetic engineering
AU3525095A (en) Deffective recombinant adenoviruses with inactivated iva2 gene
TW335389B (en) Mill additions for sealing glasses
CA2263790A1 (en) Method for immortalizing cells
AU1814995A (en) Galanin receptor, nucleic acids, transformed cells and uses thereof
AU6292694A (en) Novel polypeptide, dna coding for said polypeptide, recombinant vector containing said dna, recombinant virus prepared using said vector, and use thereof
AU1275095A (en) Antiviral composition of viral protein trans-dominant variants
AU2002309133A1 (en) Recombinant segmented negative strand virus with a duplicated 3' noncoding flanking sequence, and therapeutic compositions containing the same

Legal Events

Date Code Title Description
FG Grant or registration
MM Annulment or lapse due to non-payment of fees